title: Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
abstract: MyD88 was reported to be associated with paclitaxel sensitivity in lung cancer; however, its roles in breast cancer remain unclear. The objective of this study is to investigate the expression and function of MyD88 in breast cancer. Immunohistochemistry (IHC) was used to analyze the expression of MyD88 in both breast cancer tissues and adjacent normal tissues. Real-time PCR and Western blots were further used to measure the messenger RNA (mRNA) and protein expression. The proliferation was assessed by WST-1. Flow cytometry was used to measure the cell cycle and apoptosis. The transwell assay was used to observe the change of migration and invasion of transfected cells. In breast cancer tissues, the expression of MyD88 was significantly higher than that in tumor-adjacent normal tissues (P < 0.001). MyD88 expression was found to be associated with the differentiation stages (P = 0.019). Kaplan-Meier survival curves showed statistically significant difference on survival in patients with high expression of MyD88 compared with those with normal expression of MyD88 (P = 0.018). Knockdown of MyD88 reduced the proliferation, migration, and invasion of MCF-7 cells and increased the sensitivity of MCF-7 cells to paclitaxel treatment through the inhibition of activation of NF-κB via PI3K/Akt. Our data indicate that MyD88 may be a potential target molecule to be used in diagnosis and treatment of breast cancer.
authors.affiliation: Department of Laboratory Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Fenfen
authors.initials: F
authors.lastname: Xiang
authors.affiliation: Central Lab, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Ni
authors.affiliation: Central Lab, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Yueping
authors.initials: Y
authors.lastname: Zhan
authors.affiliation: Department of Laboratory Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Kong
authors.affiliation: Central Lab, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Jian
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Laboratory Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China.
authors.forename: Jiemin
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Department of Laboratory Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China. rong701@126.com.
authors.forename: Rong
authors.initials: R
authors.lastname: Wu
authors.affiliation: Department of Laboratory Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China. xd_kang@163.com.
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Kang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D006801:Humans; D051379:Mice; D008875:Middle Aged; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000494:pharmacology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D053594:Myeloid Differentiation Factor 88; D016328:NF-kappa B; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D017239:Paclitaxel
keywords: Breast cancer; Chemoresistance; Metastasis; MyD88; Paclitaxel